血清miR-21和CA199对胰腺癌临床诊断的应用价值探讨

目的 探讨血清miR-21和CA199对胰腺癌临床诊断的应用价值,为临床应用提供参考依据.方法 选择2015年1月至2016年6月在该院就诊的胰腺癌患者124例(癌症组),良性胰腺疾病患者100例(良性对照组)以及同期健康体检者100例(健康对照组)作为观察对象.采集其空腹静脉血,检测其血清中CA199水平和miR-21的相对表达量,分别评价两个单独应用和联合应用时对胰腺癌的诊断价值.结果 CA199在良性对照组(33.58±10.72) U/mL]和癌症组(163.74±48.53) U/mL]患者较健康对照组(7.83±4.26)U/mL]均有显著升高,miR-21仅在癌症组(6.77±2.56) U/mL]中有显著高表达(P＜0.05);在单独应用时,miR-21对诊断胰腺癌的敏感度和特异度均优于CA199(P＜0.05);联合应用时,对诊断胰腺癌的应用价值有明显升高(P＜0.05).结论 miR-21是新近发现的一种标志物,其诊断价值优于CA199,两者联合应用有助于提高对胰腺癌的诊断鉴别能力.

Clinical application value of serum miR-21 and CA199 in the diagnosis of pancreatic cancer

Objective To investigate the clinical value of serum miR-21 and CA199 in diagnosis of pancreatic cancer and provide reference for clinical application.Methods One hundred and twenty-four cases of patients with pancreatic cancer (cancer group),100 patients with benign pancreatic disease (benign control group) and 100 cases of healthy people (health control group)hospitalized in this hospital from January 2015 to June 2016 were selected.The fasting venous blood was collected,and the serum CA199 concentration and miR-21 expression were measured.The diagnostic value of two indicators alone or in combination when applied to pancreatic cancer was evaluated.Results CA199 was significantly elevated in both benign (33.58±10.72) U/mL]and cancer patients(163.74 ± 48.53) U/mL] when compared with health control group (7.83 ± 4.26)U/mL].miR-21 was only significantly higher in the cancer group (P＜0.05).When used alone,miR-21 was more sensitive to pancreatic cance than CA199 (P＜0.05).When used in combination,the diagnostic value for pancreatic cancer was significantly increased (P＜0.05).Conclusion MiR-21 is a newly discovered marker and its diagnostic value is better than CA199.The combined application can help to improve the diagnosis ability of pancreatic cancer.